Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...

By Sabrina Valle NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Q2 was a strong quarter. Today we shared positive top line data from the ATTAIN-1 orforglipron trial in people with obesity.

Dr Trevor Polischuk, Portfolio Manager of Worldwide Healthcare Trust, looks at the prosects for Eli Lilly's obesity treatments.

The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders ...

A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel ...

This year's Rose Bowl was so uncompetitive that fans paid more attention to the commercials than the actual game. To be fair, ...

Yahoo Finance Senior Reporter Brooke DiPalma tracks Thursday's top moving stocks and biggest market stories in this Market ...

Novo Nordisk developed There’s Only One Ozempic in partnership with Rogue Producer, an independent advertising and content ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...